
Research

Co-payment Vouchers, P2Y₁₂ Inhibitor Use, and Adverse Events



The cost of medications can be a barrier to the prescription of evidence-based therapy by physicians and adherence to treatment by patients. Wang and colleagues randomized 301 hospitals enrolling 11 001 adult patients with acute myocardial infarction and found that providing vouchers to offset medication co-payments for P2Y₁₂ inhibitors improved treatment persistence but did not reduce major adverse cardio-

vascular events. In an Editorial, Jackevicius and Ko suggest that further research on medication adherence should address patients' values and preferences and explore shared decision-making approaches to prescribing.

Editorial 37

■ CME jamanetwork.com/learnig Visual Abstract jama.com

Intracoronary Alteplase and Microvascular Obstruction

In patients who receive percutaneous coronary intervention for coronary thrombosis, microvascular obstruction is associated with an unfavorable cardiac prognosis. McCartney and colleagues for the T-TIME Group randomized 440 patients presenting within 6 hours of acute ST-segment elevation myocardial infarction due to occlusion of a major coronary artery and found that intracoronary alteplase given during primary percutaneous intervention did not reduce microvascular obstruction.

■ CME jamanetwork.com/learnig Visual Abstract jama.com

Linagliptin and Cardiovascular Outcomes of Type 2 Diabetes

The dipeptidyl peptidase 4 inhibitor linagliptin is effective for glycemic management of type 2 diabetes, but cardiovascular safety has not been established. Rosenstock and colleagues for the CARMELINA Investigators randomized 6991 adults with type 2 diabetes at high risk of cardiovascular and kidney disease and found that adding linagliptin to usual care resulted in a noninferior risk of a composite cardiovascular outcome over a median 2.2 years.

| Table | Tabl

Humanities

The Arts and Medicine

16 Cardiac Cruciverbalism B Haight

Poetry and Medicine

109 Garden of Endurance

JAMA Revisited IIO Prehistoric Surgery

Opinion

Viewpoint

27 Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion 5M Domchek

29 Humanizing Artificial Intelligence ST Israni and A Verghese

31 Questions for Artificial Intelligence in Health Care TM Maddox, JS Rumsfeld, and PRO Payne

33 Health as a Way of Doing Business HK Koh, SJ Singer, and AC Edmondson

A Piece of My Mind

35 The Weight of the White Coat A Goshua

Editorial

37 Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction CA Jackevicius and DT Ko

40 Medical Marketing, Trust, and the Patient-Physician Relationship SE Ortiz and MB Rosenthal

42 Medical Marketing in the United States—A Truly Special Communication H Bauchner and PB Fontanarosa

Editor's Note

96 A Tribute to Lisa M. Schwartz, MD, MS H Bauchner

LETTERS

Research Letter

102 Primary Care Nurse Practitioners and Physicians in Low-Income and Rural Areas, 2010-2016 Y Xue, JA Smith, and J Spetz

Comment & Response

105 Laryngeal Tube Insertion vs Endotracheal Intubation for Out-of-Hospital Cardiac Arrest

106 Potential Unintended Effects of Medicare's Bundled Payments for Care Improvement Program

Editor in Chief Howard Bauchner, MD 135 YEARS
OF CONTINUOUS
PUBLICATION

In This Issue of JAMA

January 1/8, 2019 Volume 321, Number 1 Pages 1-114

Clinical Review & Education

Medical Marketing in the United States

Health care organizations and companies that manufacture drugs or laboratory tests use an array of promotional activities to shape public and clinician perceptions about the benefits and harms of health care. In this Special Communication, Schwartz and Woloshin explain medical marketing strategies and their influence on health care spending. In an Editorial, Ortiz and Rosenthal suggest that trust between patients and physicians can be undermined by deceptive marketing of pharmaceuticals and health services.

G Editorial 40 and 42 Editor's Note 96

■ CME jamanetwork.com/learnig

A Man With Liver Masses and Elevated a-Fetoprotein Level





This JAMA Clinical Challenge by Mikolajczyk and colleagues presents a 55-year-old man with multifocal hepatic masses and an elevated α-fetoprotein level but without evidence of chronic liver disease. What would you do next?

Topical Hydrogen Peroxide for Seborrheic Keratoses

Seborrheic keratoses are benign, usually pigmented skin growths that generally do not require treatment but are often removed for cosmetic reasons or because they have become irritated. This Medical Letter on Drugs and Therapeutics discusses the risks and benefits of hydrogen peroxide 40% topical solution for the treatment of raised seborrheic keratoses.



JAMA Patient Page 114 Diabetic Foot Ulcers

NEWS & ANALYSIS

Medical News & Perspectives

17 Black Lung Resurgence Raises New Challenges for Coal Country Physicians

19 For Nobel Peace Prize Winner Dr Denis Mukwege, His Patients Motivate and Inspire

21 Bench to Bedside

Optimized Arylomycins May Help Address Antibiotic Resistance

23 News From the FDA

A First in Non-Hodgkin Lymphoma Treatment

Oleic Acid Can Make Heart Claim Without Hard Evidence

New Acute Myeloid Leukemia Therapy

Online @ jama.com



èď

lp

Editor's Audio Summary

Howard Bauchner, MD, summarizes and comments on this week's issue.

Visual Abstracts

"Effect of Medication Co-payment Vouchers on P2Y₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction," and "Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction"

Audio Interview



Denis Mukwege, MD, PhD, founder of Panzi Hospital in the Democratic Republic of Congo, profiled in "For Nobel Peace Prize Winner Dr Denis Mukwege,

His Patients Motivate and Inspire"

Author Audio Interview



Abraham Verghese, MD, author of "Humanizing Artificial Intelligence"

Departments

1 Staff Listing

101 CME Questions

111 Classified Advertising

112 Journal Advertiser Index

113 Contact Information

Instructions for Authors

Jama.com/public /instructionsforauthors.aspx

jama.com

JAMA January 1/8, 2019 Volume 321, Number 1